| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | KIN001-236 | GDSC1000 | pan-cancer | AAC | 0.0095 | 0.8 |
| mRNA | Cyclopamine | FIMM | pan-cancer | AAC | 0.046 | 0.8 |
| mRNA | AM-580 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | -0.0095 | 0.8 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0092 | 0.8 |
| mRNA | NSC 74859 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.8 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | -0.0087 | 0.8 |